Skip to content
Home/Companies/Biotech/Oncopeptides AB

Oncopeptides AB

Biotech·SE·Exited 2017·Held 4yr
Entry
2013
Hold
4yr
Exit
2017

Who owns Oncopeptides AB?

Oncopeptides AB was owned by HealthCap through HealthCap VI (2008 vintage) from 2013 to 2017, exited via IPO.

Hand-verified · updated 2026-08-18

HealthCap
Investor
HealthCap
HealthCap VI · 2008 · VC

Key facts

HQSE
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2017

More from HealthCap VI

Other portfolio companies in the same fund.

GenSight Biologics S.A.
Exited 2016
BiotechFrance· 2015
Glionova AB
Active
BiotechSweden· 2014
Xeris Biopharma Holdings, Inc (Strongbridge)
Exited 2021
PharmaUS· 2014
to
Nordic Nanovector AS
Exited 2015
BiotechNO· 2013
Wilson Therapeutics AB
Exited 2018
PharmaSweden· 2012
to
Ultragenyx
Exited 2014
BiotechUS· 2011

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Oncopeptides AB

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Oncopeptides AB?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Oncopeptides AB.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue